Transira Therapeutics LLC

Getzville, NY

UEI
M2NZMMLMNGK9
CAGE
7HAG0
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
106 Golden Pheasant Dr, Getzville, NY 14068, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of orally administered peptide hormones for treatment of diabetes and obesity R43DK130721 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $857,105
Development of stapled oxyntomodulin-FC fusion proteins for the treatment of diabetes and obesity R43DK117740 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $224,000

Similar vendors

Vendor Location Primary NAICS
Vireo Systems Inc. UEI Z6AJPJ82PFK3 Nashville, TN 325411 Medicinal and Botanical Manufacturing
Phoenicia Biosciences, Inc. UEI NPAHDFK9M323 Weston, MA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Biofactura Inc. UEI C1ZWQAYK4J58 Frederick, MD 325414 Biological Product (except Diagnostic) Manufacturing
Phusis Therapeutics, Inc. UEI JGZFBDAL61C4 San Diego, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Samba Biologics Inc. UEI FHEJW958JKD8 South Hero, VT 325414 Biological Product (except Diagnostic) Manufacturing

See more similar vendors on GovTribe

SBA capabilities narrative

From the vendor's SBA profile

Research and development of therapeutic peptides and proteins

Quick answers

Is Transira Therapeutics LLC registered in SAM.gov?

Yes. Transira Therapeutics LLC's SAM.gov registration is active through March 8, 2027.

What is Transira Therapeutics LLC's most recent federal award?

Transira Therapeutics LLC's most recent federal grant award is Development of orally administered peptide hormones for treatment of diabetes and obesity (R43DK130721), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 17, 2021.

On GovTribe

See Transira Therapeutics LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login